4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
NRTIs were the first anti-HIV drug class; zidovudine (AZT) was the first FDA approved medicine for HIV treatment back in 1987
[71]. After AZT, eight more NRTIs have been approved for treating the HIV infection, including didanosine (DDI) and tenofovir alafenamide (TAF), which gained FDA approval last, in 2015. NRTIs act by inhibiting HIV replication through blocking HIV RNA reverse transcriptase and have been proven to be extremely efficacious against HIV, constituting an integral part of every ART regimen. However, NRTIs, especially those of the ‘first generation’, such as AZT, DDI, zalcitabine (ddC) and stavudine (d4T), exhibit a variety of adverse events, from dyslipidemia and insulin resistance to peripheral neuropathies, myopathies, lactic acidosis and severe hepatotoxicity
[71][72][71,72]. Additionally, long term exposure to DDI has been associated with non-cirrhotic portal hypertension, a rare but serious complication
[73][74][75][76][77][73,74,75,76,77].
Mitochondrial toxicity and hypersensitivity reactions are the main mechanisms of NRTIs-induced liver damage. Mitochondrial toxicity is caused by the inhibition of mitochondrial DNA (mtDNA) replication due to the binding of NRTIs to the mitochondrial DNA polymerase gamma. This leads to an impairment of oxidative phosphorylation and promotes the formation of reactive oxygen species which in turn damage mtDNA, resulting in mitochondrial dysfunction
[78]. NRTIs also adversely affect the oxidation of free fatty acids within hepatic mitochondria, which, in combination with NRTIs-induced insulin resistance and dyslipidemia, lead to triglycerides accumulation in the liver and subsequent hepatic steatosis
[79][80][81][82][79,80,81,82].
NRTIs are the best studied drugs as far as LF is concerned (). In two large studies of HIV/HCV co-infected patients, the use of NRTIs was correlated with a worsening of LF, a higher risk of liver decompensation and increased mortality, while in another similar study from McGovern et al., the use of NRTIs, and especially DDI and d4T, were linked to liver steatosis and fibrosis
[83][84][85][83,84,85].
However, not all NRTIs carry the same risk for LF; DDI and AZT have the greatest risk. In a large study of 1785 PLWH with a 2-year follow up, higher FIB-4 values were correlated with DDI use, older age, male gender, a low CD4 + cell count, and an unsuppressed HIV viral load
[86]. In another study, previous use of DDI was associated with worse LF as estimated by FIB-4
[66]. Merchante et al., after analyzing data from 258 PLWH with no HCV or HBV co-infections assessing LF with TE, supported the claim that the duration of DDI use along with age, increased alcohol intake, previous abacavir (ABC) exposure, and a CD4 + cell count <200 cells/mL were independently associated with significant LF
[87]. Another study by Loko et al., comprising of 671 HIV/HCV co-infected patients, showed that using DDI for more than 5 months, together with male gender, a high homeostatic model assessment (HOMA) value, an intravenously acquired HCV infection and lipodystrophy were predisposing factors for significant fibrosis in TE
[88]. Similarly, Bani-Sadr et al. showed that DDI use led to a worsening of LF assessed by a liver biopsy in a cohort of 383 HIV/HCV co-infected patients under pegylated interferon and ribavirin treatment
[89]. Apart from DDI, AZT has been also associated with LF. In an observational study involving 333 PLWH, LF was evaluated with TE, FIB-4 and the AST to Platelet Ratio Index (APRI) and it was found that DDI and AZT use, HCV co-infection and ongoing HIV replication were significantly correlated with LF
[25].
Boyd A et al. also showed a progression of LF under AZT treatment in 167 HIV/HBV co-infected patients
[90]. Interestingly, in the same study tenofovir disoproxil (TDF) use did not lead to an improvement of liver fibrosis despite the efficient control of HBV infection. In a large study by Ding et al. with 3500 PLWH, of whom 2675 were HIV mono-infected, TDF was a negative predictor for LF improvement, as assessed by FIB-4
[31]. On the contrary, Vinikoor et al., supported the claim that TDF use was associated with an improvement of LF as measured by TE, irrespective of HBV-co-infection
[91]. Likewise, other studies with HIV/HBV co-infected patients found TDF to be beneficial for liver fibrosis
[92][93][94][95][92,93,94,95]. Overall TDF seems to be protective in LF, especially in patients with HIV/HBV co-infection. However, the level of LF with the FIB-4 score may be overestimated in TDF treated patients, since the FIB-4 scoring system incorporates the aspartate aminotransferase (AST) value which may rise in clinical or subclinical muscle damage due to TDF use.
Although many studies have focused on DDI, AZT and TDF, there is insufficient data for the rest of the NRTIs regarding their potential to induce LF. In a study of 112 HIV/HCV co-infected patients undergoing a liver biopsy, it was shown that the use of d4T led to liver steatosis and that patients with steatosis were more prone to develop worse LF. A combination of ABC and lamivudine (3TC) as backbone therapies were shown to increase the APRI score in a cohort of 314 HCV/HIV co-infected Canadian patients while exposure to ABC alone was found to have a negative impact on liver stiffness in a cohort of PLWH without co-infections
[87][96][97][87,96,97]. Finally, Emtricitabine (FTC) has not been linked to hepatotoxicity and is considered safe in terms of LF
[98].
5. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
NNRTIs are non-competitive inhibitors of reverse transcriptase affecting the catalytic function of the enzyme by binding to specific tyrosine residues located near the active site
[99]. The most common mechanisms attributed to NNRTI hepatotoxicity include a hypersensitivity reaction occurring early during the treatment course and an idiosyncratic late-onset toxicity of metabolic origin; both seem to be more common in patients with HBV or HCV co-infections, although this finding is not constant in all studies
[100][101][102][103][104][105][100,101,102,103,104,105]. Not all NNRTIs carry the same risk for hepatotoxicity and patients receiving nevirapine (NVR) and efavirenz (EFV) display a risk of up to 18% and 8%, respectively
[106].
Regarding the association of NNRTIs with LF, data are scarce
(). In a cross-sectional study of 152 HIV/HCV co-infected patients, NVR use was found to induce severe LF, although the duration of the exposure was not associated with LF severity
[107]. On the contrary, in a study of 201 HIV/HCV co-infected patients whose LF was assessed by a liver biopsy, NNRTIs and especially NVR were found to be associated with a low probability of significant LF, a finding not observed in patients treated with PIs
[108]. Likewise, in another study by Fernández-Montero et al. including 545 HIV/HCV co-infected patients, NVR was found to be protective against LF progression
[109]. The safety of EFV in patients with liver cirrhosis was studied in a cohort of 189 HIV/HCV co-infected patients, of whom 56 had severe LF and 25 had liver cirrhosis. EFV was proven to be quite safe, with few cases presenting severe transaminitis, low rates of EFV discontinuations due to liver-related events and no deaths due to liver disease progression
[110]. To further complicate the role of NNRTI in LF, Rilpivirine (RPV) use in mice ameliorated LF through a selective STAT 1-dependent induction of apoptosis in hepatic stellate cells, which exerted paracrine effects in hepatocytes promoting liver regeneration
[111].
6. Protease Inhibitors (PIs)
PIs are peptidomimetic molecules that target the active site of HIV aspartic protease, the enzyme responsible for cleaving the precursor viral polyprotein, gagpol, into its constituent proteins. The inhibition of viral polyprotein cleavage results in the production of immature non-infectious viral particles. All FDA-approved PIs have been associated with cases of hepatitis even though the exact mechanism is largely unknown
[104]. However, this drug-induced hepatitis usually resolves itself spontaneously and progressive liver damage occurs rarely
[112][113][114][115][116][112,113,114,115,116].
First generation PIs—e.g., indinavir and ritonavir—are known to induce IR, mainly through dramatically increasing the central adiposity and altering the plasma lipid profile via lipogenesis inhibition, decreasing the hepatic clearance of very-low-density lipoproteins (VLDL), and increasing the production of hepatic triglyceride
[117][118][119][117,118,119]. Although the new-generation PIs seem to have little impact on lipid levels as monotherapy, they contribute to an unfavorable lipid profile compared to most other classes of ART when combined with ritonavir or cobicistat in the context of a pharmacological booster
[120][121][122][123][120,121,122,123].
No cases of severe PI-related LF have been reported in the literature, even though IR seems to be a common adverse effect in clinical practice and cases of indinavir-induced hepatitis have been described
[124][125][126][124,125,126]. In a study by Fernandez-Montero et al., the use of PIs, mainly Lopinavir, was associated with the progression of LF in a cohort of 545 HIV/HCV co-infected patients, while in a study by Sagir et al., the duration of PI use was positively correlated with LF
[109][127][109,127]. On the contrary, in a study by Benhamou et al., comprising of 182 HCV/HIV co-infected patients, PLWH using PIs were found to have less LF
[128]. Likewise, in a study by Macias et al., the use of PI-based ART led to less LF when compared to no ART
[129]. Finally, ritonavir was not found to cause severe hepatotoxicity in a cohort of 117 HCV/HIV co-infected patients, 71 of whom had significant LF, while in another study, switching from ritonavir-boosted PI-based ART to raltegravir-based ART led to a lower level of liver steatosis but not LF
[130][131][130,131]. The most important studies regarding PIs and LF are summarized in .
7. Integrase Strand Transfer Inhibitors (INSTIs)
INSTIs target the integration process of the HIV viral DNA into the host DNA, a process achieved through a series of DNA cutting and joining reactions, mediated by the retroviral enzyme integrase
[132][133][132,133]. Current INSTIs target the strand transfer step of the integration process by binding to the active enzyme site and disengaging it from the viral DNA
[134]. Five INSTIs are currently in use against HIV with the most recent one, Cabotegravir, obtaining FDA approval in January 2021 as a monthly injection
[135][136][135,136]. Even though all INSTIs are largely metabolized in the liver by glucuronidation following urinary clearance, they have little or no effect on microsomal cytochrome P450 enzymes and their mechanism of hepatotoxicity is unknown
[137].
Overall, INSTIs are considered safe and potent ART drugs; severe transaminitis is a rare event
[138][139][138,139]. Weight gain under INSTIs treatment has been noted, especially in PLWH treated with dolutegravir (DTG), however the impact on liver steatosis remains controversial, since a study from China correlated the use of INSTIs with steatosis, but two other studies showed an improvement in liver steatosis after switching from PIs to ART including INSTIs
[130][140][141][142][143][130,140,141,142,143].
Given the lack of data in the literature relating the use of INSTIs to significant LF, and that hepatotoxicity is a rare adverse event of INSTIs, it appears that INSTIs are a safe therapeutic option for patients with liver diseases.
8. Entry Inhibitors
Entry inhibitors act by preventing HIV from entering into the host cell
[144]. So far, the following entry inhibitors have been approved for HIV treatment and are currently used in clinical practice: (a) Maraviroc (MVC), a C-C chemokine receptor-5 (CCR-5) inhibitor which prevents the interaction of CCR-5 with envelope glycoprotein GP-120 (gp120); (b) Enfuvirtide, a ‘fusion inhibitor’ which binds to the transmembrane glycoprotein GP-41 (gp41) preventing the outer membrane of HIV from fusing to the approximate membrane of T-cells and the subsequent cell entry; (c) Idalizumab which binds to domain 2 of CD4 + T-cells and interferes with the post-attachment steps required for the entry of HIV particles into the host cells; and (d) Fostemsavir, approved by the FDA in 2020, which binds directly to gp120 prohibiting the interaction needed between the virus and the surface receptors on CD4 + T-cells
[145][146][145,146].
All entry inhibitors have proven to be liver-friendly, even in cirrhotic patients; transaminitis or the deterioration of the liver function are rather rare adverse events
[147][148][149][147,148,149]. When hepatotoxicity occurs, this is probably due to drug-drug interactions since entry-inhibitors are extensively metabolized in the liver via the CYP 450 system and are a substrate for P-glycoprotein.
Data regarding entry inhibitors and liver fibrosis are few and mainly concern MVC. In an experimental study by Coppola et al., the addition of MVC in the hepatic stellate cell line blocked the accumulation of fibrillar collagens and the production of extracellular matrix proteins along with a down-regulation of metalloproteinases 2 and 9 (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2)
[150]. In another study by Rossetti et al. in a cohort of 150 patients, switching from an MVC-free 3 drug regimen ART to MVC plus Darunavir/ritonavir led to a better APRI score after 48 weeks.
9. Conclusions
ART has changed the landscape of HIV infection, increasing the lifespan of PLWH and changing the major causes of morbidity and mortality. However, concern has risen regarding the short and long-term hepatotoxicity of ART. Several studies have attempted to address this issue, but many controversies still exist, since the same drugs have been found to carry a significant risk for LF in one study, and minimal or no risk in another.
According to most studies, ‘first generation’ NRTIs, mainly DDI and AZT, may lead to significant LF after long-term treatment, a possibility that is decreasing with ‘new generation’ NRTIs, such as TDF or FTC. On the other hand, NNRTIs have not been implicated into fibrogenesis, with the exception of NVR, while the same applies for INSTIs. Surprisingly, even though PIs are known to cause insulin resistance and weight gain, data are controversial with some studies showing an improvement while others showing a worsening of LF under PI-containing ART regimens. Lastly, entry inhibitors seem to carry a minimal risk for hepatotoxicity or significant LF.
In conclusion, a reasonable therapeutic strategy is to avoid using ‘first generation’ NRTIs in PLWH with predisposing factors for LF or established, significant LF, and choose ‘new generation’ NRTIs or other ART-class drugs instead.